Robert Rauker, CEO, offers an overview of the Belluscura’s (BELL ) portable oxygen concentrator device, it’s advantages and product roadmap including both new and next generation products. Robert also discusses use of funds which includes regulatory clearance, staffing and marketing as most R&D costs have already been covered leading the expected breakeven within two years.
Tony Dyer, CFO, discuses the business model and size and expected growth of the supplemental oxygen markets which was estimated at 6% pre COVID but has increased to 11% post COVID. Tony elaborates on FDA and international clearance and their future regulatory pathway.